Bellevue Group’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.87M | Sell |
56,253
-40,154
| -42% | -$4.19M | 0.13% | 78 |
|
|
2025
Q1 | $11.2M | Sell |
96,407
-22,523
| -19% | -$2.63M | 0.25% | 71 |
|
|
2024
Q4 | $10.1M | Sell |
118,930
-248,251
| -68% | -$21M | 0.19% | 80 |
|
|
2024
Q3 | $33M | Sell |
367,181
-149,352
| -29% | -$13.4M | 0.53% | 57 |
|
|
2024
Q2 | $41.6M | Sell |
516,533
-168,943
| -25% | -$13.6M | 0.68% | 37 |
|
|
2024
Q1 | $54.7M | Buy |
685,476
+50,104
| +8% | +$4M | 0.83% | 32 |
|
|
2023
Q4 | $50.6M | Buy |
635,372
+3,885
| +0.6% | +$309K | 0.77% | 42 |
|
|
2023
Q3 | $44.1M | Buy |
631,487
+57,124
| +10% | +$3.99M | 0.71% | 42 |
|
|
2023
Q2 | $41.3M | Buy |
574,363
+133,013
| +30% | +$9.56M | 0.59% | 56 |
|
|
2023
Q1 | $27.2M | Buy |
441,350
+4,692
| +1% | +$289K | 0.4% | 67 |
|
|
2022
Q4 | $33.7M | Sell |
436,658
-59,866
| -12% | -$4.62M | 0.45% | 64 |
|
|
2022
Q3 | $22.2M | Sell |
496,524
-320,617
| -39% | -$14.3M | 0.32% | 78 |
|
|
2022
Q2 | $31.3M | Buy |
817,141
+97,659
| +14% | +$3.74M | 0.44% | 64 |
|
|
2022
Q1 | $29.8M | Buy |
719,482
+67,545
| +10% | +$2.8M | 0.35% | 82 |
|
|
2021
Q4 | $24.6M | Sell |
651,937
-101,008
| -13% | -$3.82M | 0.25% | 97 |
|
|
2021
Q3 | $24.8M | Buy |
752,945
+400,924
| +114% | +$13.2M | 0.25% | 98 |
|
|
2021
Q2 | $23.7M | Buy |
+352,021
| New | +$23.7M | 0.23% | 102 |
|